JP2018511628A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511628A5
JP2018511628A5 JP2017553879A JP2017553879A JP2018511628A5 JP 2018511628 A5 JP2018511628 A5 JP 2018511628A5 JP 2017553879 A JP2017553879 A JP 2017553879A JP 2017553879 A JP2017553879 A JP 2017553879A JP 2018511628 A5 JP2018511628 A5 JP 2018511628A5
Authority
JP
Japan
Prior art keywords
seq
group
alkyl
formula
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017553879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511628A (ja
Filing date
Publication date
Priority claimed from GBGB1506393.6A external-priority patent/GB201506393D0/en
Application filed filed Critical
Publication of JP2018511628A publication Critical patent/JP2018511628A/ja
Publication of JP2018511628A5 publication Critical patent/JP2018511628A5/ja
Pending legal-status Critical Current

Links

JP2017553879A 2015-04-15 2016-04-15 部位特異的な抗体−薬物複合体 Pending JP2018511628A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506393.6A GB201506393D0 (en) 2015-04-15 2015-04-15 Site-specific antibody-drug conjugates
GB1506393.6 2015-04-15
PCT/EP2016/058371 WO2016166299A1 (en) 2015-04-15 2016-04-15 Site-specific antibody-drug conjugates

Publications (2)

Publication Number Publication Date
JP2018511628A JP2018511628A (ja) 2018-04-26
JP2018511628A5 true JP2018511628A5 (enExample) 2019-05-09

Family

ID=53333825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553879A Pending JP2018511628A (ja) 2015-04-15 2016-04-15 部位特異的な抗体−薬物複合体

Country Status (11)

Country Link
US (1) US20180125994A1 (enExample)
EP (1) EP3283118A1 (enExample)
JP (1) JP2018511628A (enExample)
KR (1) KR20170137115A (enExample)
CN (1) CN107683146A (enExample)
AU (1) AU2016249877A1 (enExample)
BR (1) BR112017022256A2 (enExample)
CA (1) CA2981920A1 (enExample)
GB (1) GB201506393D0 (enExample)
MX (1) MX2017013154A (enExample)
WO (1) WO2016166299A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3047686C (en) 2017-02-08 2020-07-07 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP3544636B1 (en) 2017-02-08 2021-03-31 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
JP2020517609A (ja) 2017-04-18 2020-06-18 メディミューン リミテッド ピロロベンゾジアゼピン複合体
EP3612235A1 (en) * 2017-04-20 2020-02-26 ADC Therapeutics SA Combination therapy with an anti-psma antibody-drug conjugate
BR112019021680A2 (pt) 2017-04-20 2020-05-12 Adc Therapeutics Sa Terapia de combinação com conjugado anticorpo-fármaco anti-cd25??
US11426467B2 (en) 2017-06-14 2022-08-30 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD25 ADC
EA039276B1 (ru) 2017-08-18 2021-12-27 Медимьюн Лимитед Пирролобензодиазепиновые конъюгаты
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201820725D0 (en) 2018-12-19 2019-01-30 Adc Therapeutics Sarl Pyrrolobenzodiazepine resistance
US20220347309A1 (en) 2018-12-19 2022-11-03 Adc Therapeutics Sa Pyrrolobenzodiazepine resistance
BR112021018260A2 (pt) 2019-03-15 2021-11-23 Medimmune Ltd Dímeros de azetidobenzodiazepina e conjugados compreendendo-os para uso no tratamento de câncer
RS63715B1 (sr) * 2019-03-29 2022-11-30 Medimmune Ltd Jedinjenja i njihovi konjugati
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
TW202140076A (zh) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN118176213B (zh) * 2021-08-27 2025-09-23 詹森生物科技公司 抗psma抗体及其用途
CN116370651A (zh) * 2023-04-04 2023-07-04 上海愿智生物技术有限公司 一种抗psma抗体-药物缀合物及其制备方法和应用
WO2025145034A1 (en) * 2023-12-29 2025-07-03 T.O.A.D. Oncology Sa Anti-psma conjugates and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL199659B1 (pl) * 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
JP2008521828A (ja) * 2004-11-29 2008-06-26 シアトル ジェネティックス, インコーポレイテッド 操作された抗体およびイムノコンジュゲート
US10435458B2 (en) * 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
JP6014596B2 (ja) * 2010-11-09 2016-10-25 メディミューン,エルエルシー 均一コンジュゲーションのための抗体足場
HUE041274T2 (hu) * 2012-10-12 2019-05-28 Adc Therapeutics Sa Pirrolobenzodiazepin-anti-PSMA-antitest konjugátumok
WO2014057114A1 (en) * 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
WO2015031693A1 (en) * 2013-08-28 2015-03-05 Stem Centrx, Inc. Engineered anti-dll3 conjugates and methods of use

Similar Documents

Publication Publication Date Title
JP2018511628A5 (enExample)
JP2018516243A5 (enExample)
JP2018502902A5 (enExample)
JP2020506951A5 (enExample)
JP2020531471A5 (enExample)
JP2016508130A5 (enExample)
RU2019122802A (ru) Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы
JP2018516860A5 (enExample)
RU2019138337A (ru) Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии
JP2020514419A5 (enExample)
JP2014527974A5 (enExample)
JP2014528466A5 (enExample)
JP2020524174A5 (enExample)
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP2014528467A5 (enExample)
JP2017518040A5 (enExample)
JP2018070648A5 (enExample)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
JP2013505946A5 (enExample)
JP2016531915A5 (enExample)
JP2017506234A5 (enExample)
JP2020519643A5 (enExample)
JP2017528467A5 (enExample)
JP2021506788A (ja) 生物学的に活性な化合物を含むイオン性ポリマー
HRP20211710T1 (hr) Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat